Current Edition


FDA, as expected, rejects Lilly and Innovent immunotherapy in signal to drugmakers

Dive Brief: The Food and Drug Administration has rejected an experimental cancer immunotherapy Eli Lilly and partner Innovent Biologics have been developing for a common …

Continue Reading →

Innovent receives IND approval to initiate Clinical Trials in China

Innovent’s IBI101, is the first OX40-targeted molecule to receive IND approval in China Innovent Biologics, a world-class China-based biopharmaceutical company that develops and intends to …

Continue Reading →